



Published in final edited form as:

Nat Immunol. ; 13(8): 722–728. doi:10.1038/ni.2366.

IL-12 Family Cytokines: Immunological Playmakers

Dario A.A. Vignali¹ and Vijay K. Kuchroo²

¹Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA

²Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA

Abstract

The interleukin-12 (IL-12) family is unique in comprising the only heterodimeric cytokines, which includes IL-12, IL-23, IL-27 and IL-35. This endows these cytokines with a unique set of connections and functional interactions not shared within other cytokine families. Despite sharing many structural features and molecular partners, they mediate surprisingly diverse functional effects. Here we discuss the unique and unusual structural and functional characteristics of this cytokine family. We outline how cells might interpret seemingly similar cytokine signals to give rise to the diverse functional outcomes which characterize this cytokine family. We will also discuss the therapeutic implications of this complexity.

Within the vast array of bioactive cytokines, the interleukin-12 (IL-12) family is unique. They are the only heterodimeric cytokine family and this endows them with several unique and distinctive features. It also presents a number of molecular and functional realities that provide unprecedented opportunities for positive and negative feedback control, some of which may remain unrealized. Chain pairing promiscuity is a common feature of this heterodimeric cytokine family which currently includes IL-12, IL-23, IL-27 and IL-35 (Box 1)^{1,2}. Despite many structural similarities in the cytokines, their receptors and downstream signaling components, they possess vastly contrasting biological activities which belie their common features. IL-12 and IL-23 are predominantly proinflammatory/prostimulatory cytokines which contribute key roles in the development of Th1 and Th17 cells, respectively^{3–5}. Although IL-27 was initially thought to be a proinflammatory cytokine with some recent observations supporting this view⁶, the majority view is that IL-27 is an immunoregulatory cytokine^{7–9}. IL-35, the newest member of this family, is a potent inhibitory cytokine produced by natural, thymus-derived regulatory T cell (nT_{reg}) populations^{1,10}. This establishes a functionally balanced dichotomy within this family with IL-12 and IL-23 being positive regulatory while IL-27 and IL-35 are negative regulators (Fig. 1).

Correspondence should be addressed to D.A.A.V. (vignali.lab@stjude.org).

COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests.

Box 1**Composition of the IL-12 cytokine family, their receptors and signaling components**

The heterodimeric IL-12 family cytokines consist of an α chain (p19, p28 or p35) and a β chain (p40 or Ebi3) (Fig. 1)^{1,2}. Alpha chains have a four helix bundle structure characteristic of the IL-6 superfamily, to which the IL-12 family belongs. In contrast, the β chains share homology with soluble class I cytokine receptor chains, such as IL-6R α . The p40 chain can pair with p35 or p19 to form IL-12 or IL-23, respectively, while Ebi3 can pair with p28 or p35 to form IL-27 or IL-35, respectively (Fig. 1)^{39,49,58,69,70}.

The receptor chains are also utilized by multiple cytokines (Fig. 1)^{1,2}. IL-12 signals via IL12R β 1 and IL12R β 2^{48,71,72}, while IL-23 signals through IL12R β 1 and IL23R^{69,73}. In contrast, IL-27 utilizes gp130 and WSX-1⁷⁴, while IL-35 signals via gp130 and IL12R β 2²⁸. IL-35 is unusual in that it can also signal via two additional receptor chain compositions; gp130-gp130 and IL12R β 2-IL12R β 2 homodimers²⁸.

Signaling via all of these receptors is mediated by members of the Janus kinase-signal transducers and activators of transcription (JAK-STAT) family^{27,75,76} (Fig. 1). JAK2 and either JAK1 or TYK2 appear to mediate phosphorylation of the IL-12 cytokine receptors family-associated STATs. IL-12 mediates signaling via pSTAT4⁷⁷, IL-23 via pSTAT3 and pSTAT4^{69,73}, IL-27 via pSTAT1 and pSTAT3^{78,79}, and IL-35 via pSTAT1 and pSTAT4²⁸. For IL-35, formation of a STAT1:STAT4 heterodimer is required for Ebi2/Il12a transcription, but partially dispensable for suppression²⁸.

Here we discuss the implications of the unique structural and functional features of the IL-12 cytokine family and how this leads to a greater level of control and crosstalk than is typically observed in other cytokine families. We will also discuss what remains to be determined and speculate on additional layers of complexity that may exist, and assess how these features may complicate the therapeutic targeting and utilization of this fascinating cytokine family. We will primarily focus on the molecular aspects of these cytokines and their effect on T cell differentiation, acknowledging that they also affect other cell populations and impact a wide variety of disease conditions which have been extensively covered in other reviews (Box 2)^{1,4,11-16}.

Box 2**The IL-12 Cytokine Family Resume**

IL-12 is a pro-inflammatory cytokine produced by DCs, macrophages and B cells in response to microbial pathogens^{34,80}. A positive feedback loop is established where by IL-12 induced IFN γ production by T cells which primes additional APCs for IL-12 production and facilitates Th1 differentiation. IL-12 can also induce production of IFN γ by NK cells.

IL-23, like IL-12, is a pro-inflammatory cytokine that is also produced by activated DCs and macrophages in response to microbial pathogens which is enhanced by CD40-

CD40L interactions^{4,14,81}. It also induces expression of IL23R creating a positive feedback loop that enhances IL-23 expression. However, it differs from IL-12 in playing a key role in Th17 development by stabilizing IL-17 expression and the Th17 phenotype, but is not a differentiation factor for Th17 cells⁸². In addition, IL-23 is critical for inducing a pathogenic phenotype in Th17 cells. TLR2 and Dectin-1 signaling by fungal products like Zymosan induces IL-23 induction and promotes Th17 differentiation.

IL-27 has been reported to have both pro-stimulatory and inhibitory functions^{6,7,81,83,84}, although accumulating data supports a role for IL-27 in inhibiting immune responses. Activation of APCs with TLR agonists (TLR3, 4 and 7/8) induces IL-27 and IFN β synergies with TLR mediated IL-27 expression^{85,86}. It is often generated during the resolution phase of an autoimmune response by local APCs. Furthermore, diverse stimuli including T_{regs}, IFN γ and statins can induce IL-27 production by APCs and thereby limit induction of inflammation. Although IL-27 alone has no apparent stimulatory properties, it can induce IFN γ production by T cells and NK cells in combination with IL-12 and/or IL-2³⁹. IL-27-induced signaling can mediate STAT1-driven T-bet expression. IL-27 can also modulate T cell proliferation depending on the presence of IL-2. IL-27 can inhibit IL-2 production limiting nT_{reg} and T cell proliferation, but IL-2 can inhibit these effects by inhibiting WSX1 expression^{35,36}. IL-27 can inhibit development of Th17 cells and induce the development of an IL-10-producing Tr1-like regulatory population, in part by induction of c-Maf⁴⁰⁻⁴³. IL-27-induced c-Maf expression can also facilitate Tfh development via induction of IL-21 and thereby modulates B cell development and function^{84,87}.

IL-35 appears to be exclusively produced by regulatory T cell populations^{1,10}. It is produced by mouse and human nT_{regs} and is required for their maximal suppressive capacity^{49,61}. Indeed, genetic deletion or antibody-mediated blockade of IL-35 blocks nT_{reg}-mediated suppression via by soluble factors. IL-35 suppresses T cell proliferation by inducing cell cycle arrest in G₁ without inducing apoptosis^{49,51,88}. Like TGF β and IL-10, IL-35 can induce the development of an induced regulatory T cell (iT_{reg}) population, iT_{reg}35, that suppress via IL-35 but does express Foxp3, IL-10 or TGF β ^{51,61}. Interestingly, human and mouse nT_{reg}-mediated inhibition converts the suppressed target T cell population into iT_{reg}35, which appear to contribute to the regulatory milieu in inflammatory sites, such as solid tumors^{51,61}. More recently, several groups have shown that IL-35 appears to perform an immunomodulatory role in a wide variety of disease conditions^{51,88-95}. Thus it appears that IL-35 may be most influential at sites of high inflammation and strong nT_{reg} activation

Variations on a Theme: Promiscuity in Cytokine and Receptor Pairing

Chain sharing is a key feature of the IL-12 cytokine and cytokine receptor family (Box 1; Fig. 1)^{1,2}. Both cytokine β chains are components of two cytokines, while at least one α chain (p35) is also a constituent of two cytokines (IL-12 / IL-35). The rationale for this propensity is unclear. It could just be expedient to create multiple biologically diverse moieties from the same building blocks. Alternatively, it could help maintain immune balance such that deletion or disruption of a single protein or gene removes positive and

negative components from the immune repertoire. While this may seem a sound argument in the case of p35 or IL12R β 2, components of IL-12, IL-35 and their receptors, this argument breaks down when one considers the consequences of losing p40, Ebi3 or IL12R β 1, which would preferentially impact one side of this immune equation (Fig. 1).

Given this propensity for chain sharing, one also wonders if other combinations, such as p40/p28 and Ebi3/p19, can pair and perform physiologically relevant functions or whether the IL-12 family α/β chains can pair with other relatives within the IL-6 cytokine superfamily. Indeed, a recent study has suggested that p28 can pair with cytokine-like factor 1 (CLF) to generate a cytokine that regulates NK and T cell activity via IL6R α .¹⁷ A complete picture of all the physiologically relevant interactions could provide the important insight required to complete this immunological jigsaw.

The existence of a heterodimeric cytokine family that shares components may also provide a unique mechanism to control cytokine secretion and stability. Interestingly, the pairing efficiency and the capacity of the individual components to be secreted alone or in combination with other cytokines are vastly different. For instance, IL-12 and IL-23 are disulphide-linked heterodimers and are secreted efficiently, while IL-27 and IL-35 lack this disulphide, pair poorly and thus are secreted in vastly reduced amounts (especially IL-35)^{2,18–21}. This raises the possibility that in cells that express multiple IL-12 cytokine family chains, such as activated DC, macrophages or B cells, they may compete for pairing and secretion. Given the apparent stability of IL-12 and IL-23, they may dominate over IL-27 or IL-35. Thus, more studies are warranted to determine if this competition dynamic does occur and if so whether it has a physiologic impact. It is also curious that the two positive regulatory cytokines (IL-12/IL-23) are disulphide linked while the two negative regulatory cytokines (IL-27/IL-35) are not. Whether this is coincidental or establishes a valid structure-function link remains to be determined.

In addition to their canonical function as heterodimers, some of the IL-12 family components can function autonomously as monomers or homodimers. For instance p28 alone (also referred to as IL-30), in the absence of its normal partner Ebi3, has been shown to bind to but not signal via gp130, thereby antagonizing IL-6 and IL-27 receptor signaling, limiting IL-17 and IL-10 production, respectively, and inhibiting germinal center formation and antibody production²². In contrast, there is no clear evidence suggesting that p19 or p35 can be secreted without a partner. Homodimers of p40 have been shown to antagonize IL-12-driven responses by competing for its binding to IL12R β 1 while retaining the capacity to activate DCs^{23–26}. While Ebi3 can be secreted, the extent to which this occurs and its physiological impact are unknown. Taken together, there are hints that IL-12 family monomers or homodimers could impact the function of their heterodimeric siblings, and/or immune function in general, although more analysis is clearly required.

The chain sharing theme also extends to receptor usage with several cytokines utilizing the same receptor chains (Box 1; Fig. 1)^{1,2,27}. For instance, IL12R β 1 is a component of the IL-12 and IL-23 receptors, IL12R β 2 is used by IL-12 and IL-35, and gp130 is bound by IL-27 and IL-35. As these receptors chains are expressed as monomers and dimerize following cytokine ligation, it remains unclear whether this receptor sharing creates

competition for binding when cells are exposed to multiple IL-12 family cytokines. Given that competition of receptor binding is the paradigm under which p28 operates²², it is possible that this may also occur with the heterodimers thereby providing an additional level of immune regulation. For instance, could IL-27 and IL-35 compete for gp130, could IL-12 and IL-23 compete for IL12R β 1, or could IL-12 and IL-35 compete for IL12R β 2? Indeed, could p28/IL-30 inhibit IL-35 binding given that it also utilizes gp130?^{22,28}

An additional layer of complexity has recently been revealed by the observation that IL-35 can also ligate and signal via gp130-gp130 and IL12R β 2-IL12R β 2 homodimers²⁸. While this appears to be a unique feature of IL-35 not shared by other members of the IL-12 cytokines family, it is not without precedent as gp130 can also signal as a homodimer following ligation with IL-6:sIL6R α complexes or viral IL-6^{29,30}. How this impacts the function of IL-35 compared with its other IL-12 family siblings remains to be determined.

In summation, an unprecedented level of internal regulation may occur within the IL-12 family due to the extensive known, and potential, cytokine and receptor chain sharing and interaction. It is possible that the full complexity of this network remains to be fully realized.

Immunological Playmakers: IL-12 Family Cytokines Shape Immune Responses

In many respects, the IL-12 cytokine family epitomizes the central tenet of immunoregulation. IL-12 and IL-23 are pro-inflammatory/pro-stimulatory cytokines, while IL-27 and IL-35 are inhibitory cytokines (Box 2, Fig. 1)^{1,3-5,7-10}. This raises the possibility that there is an unappreciated spectrum of immune balance that is established by, and within, the IL-12 cytokine family. This is impacted by multiple positive and negative feedback loops and interactions that modulate many aspects of immune function (Fig. 2)^{1,3-5,7-10}. In addition to modulating the behavior of multiple T cell populations, the IL-12 cytokine family has a substantial impact on the direction of immune responses and a wide variety of diseases by also controlling the development of many contrasting T cell populations. Many of the immunoregulatory properties of this cytokine family are due to their effects on T cell differentiation and function. Whereas IL-12 and IL-23 can induce or promote generation of proinflammatory Th1 and Th17 cells, IL-27 and IL-35 can induce regulatory Tr1 cells and iTr35 cells, respectively. In addition, these cytokines can cross-regulate the development of other T cell subsets directly or indirectly through the induction of regulatory T cell populations (Tr1 and iTr35). The most profound example is that IL-27 suppresses development of proinflammatory Th17 cells by inhibiting key transcription factors in Th17 differentiation and at the same time induces the development of Tr1 cells that suppress immune responses by multiple, distinct mechanisms (Fig. 2). In this regard one might argue that the IL-12 cytokine family has a greater impact in shaping immune responses than any other cytokine family.

In deciphering the multiple layers of interaction and influence, it is helpful to examine the impact of the IL-12 cytokine family on differentiation of specific T cell subsets. Several IL-12 family cytokines impact Th1 and Th17 development. The capacity of IL-12 to drive Th1 development is well known, while Th17 development is facilitated by IL-23. As one

would expect, this is governed to a large extent by regulated receptor expression. Naïve T cells express IL12R β 1 and gp130 but not IL12R β 2, IL23R and WSX1^{31–33}. While TCR signaling with co-stimulation via CD28 is sufficient to induce IL12R β 2, expression is enhanced by IL-27, as well as IL-2, tumor-necrosis factor α (TNF α) and IFN γ . In contrast, TCR signaling is not sufficient to induce IL23R expression. Cytokines that induce STAT3 activation are the most potent drivers of IL23R expression. STAT3 plus ROR γ t cooperate to transactivate IL-23 and IL23R thereby facilitating a positive feed-forward loop which enhances IL23R, IL-17 and IL-22 expression, and stabilizes the Th17 phenotype. In addition, IL-12 and IL-27 impact Th17 development by inhibiting key transcription factors (ROR γ t, ROR α) that induce Th17 differentiation. In addition, IL-12 and IL-27 can act on differentiating Th17 cells by regulating expression of receptors for other IL-12 family members and making them responsive to inhibitory cytokines and thus inducing IFN γ from developing Th17 cells. Similarly, IL-12 can also enhance APC production of p19, and component of IL-23, thereby limiting Th1 and favoring Th17 development³⁴.

IL-27 can limit Th development in general by blocking IL-2 production which is required for early T cell proliferation^{35,36}. However, once IL-2 production is initiated, the influence of IL-27 can be limited by the IL-2-driven downregulation of WSX1^{37,38}. IL-27 was initially thought to be a prostimulatory cytokine by virtue of its capacity to enhance the production of IFN γ in the presence of low concentrations of IL-12³⁹. However the function of IFN γ , or any cytokine for that matter, can be greatly influenced by co-secreted cytokines. IL-27 is also a potent inducer of IL-10 which in combination with IFN γ represses Th17 cells and promotes Tr1 cells^{40–43}. This is also facilitated by the IL-27-mediated induction of STAT1 which blocks ROR γ t expression⁴⁴ and induction of transcription factors cMaf and AhR, growth factor IL-21 and costimulatory molecule ICOS, which coordinately act to induce Tr1 differentiation^{43,45}. IL-27 induces both IFN γ and IL-10 in developing Tr1 cells, and both IFN γ and IL-10 are utilized in the regulation of other effector T cell subsets. Whereas IL-10 was crucial for suppressing immune responses at multiple levels, IFN γ produced by Tr1 cells was shown to suppress the development of Th17 cells⁴⁶, therefore both of these cytokines produced by Tr1 cells are utilized for immunoregulation. IL-27 has been shown to suppress Th17 cells and induce Tr1 cells in human T cells as well, by a AhR/cMaf dependent mechanism⁴⁷.

IL-35 can block the development of Th1 and Th17 cells by limiting early T cell proliferation and thus expression of key differentiating transcription factors and cytokines required for their differentiation (Chaturvedi & D.A.A.V., unpublished observations). IL-35 is unusual in having three receptors (IL12R β 2:gp130; IL12R β 2:IL12R β 2; gp130:gp130), which is likely to substantially expand its sphere of influence²⁸. While IL12R β 2 is expressed mainly by activated T cells and NK cells, gp130 is fairly ubiquitously expressed⁴⁸. Consequently, naïve T cells can be suppressed by IL-35^{49–51}. IL-2 or IL-27 pretreatment upregulates IL12R β 2 and thus increases T cell sensitivity to IL-35-mediated suppression²⁸. Given the suppressive phenotype of IL-27 one wonders whether some of this activity is mediated by increased sensitivity to IL-35.

Although IL-35 can inhibit Th1 proliferation, it has no effect on Th17 proliferation perhaps due to limited receptor expression. This may provide further insight into the resistance of

Th17 cells to nT_{reg}- mediated suppression¹⁰. Interestingly, it has been suggested that IL-23 may also contribute to Th17 resistance to nT_{reg}-mediated suppression via $\gamma\delta$ T cells, although the mechanism remains unclear⁵². Although IL-35 can inhibit Th1 proliferation, they are resistant to iT_{reg} conversion due to the potent inhibition of *Ebi3* and *Iil2a* transcription by IFN γ (Th1-produced or added exogenously; V.C. & D.A.A.V., unpublished observations). Given the IL-12 can induce IFN γ , it is possible IL-12 may also limit iT_{reg} conversion indirectly.

IL-12 family cytokines can also impact Th2 cells. Whereas IL-12 will inhibit IL-4 production and antagonize Th2 responses¹¹, IL-35 blocks Th2 development by repressing GATA3 and IL-4 expression and limiting Th2 proliferation (V.C. & D.A.A.V., unpublished observations). IL-35 can also mediate iT_{reg} conversion from Th2 cells, although this can be blocked by IFN γ .

Synonymous with the effects of these cytokines on effector populations, IL-12 family cytokines can also impact regulatory T cell development, homeostasis and function. T_{regs} are highly dependent on IL-2 for effective proliferation and homeostasis^{53,54}. IL-12 and IL-27 can limit IL-2 production and consequently have been shown to negatively impact nT_{regs}^{36, 55–57}. Conversely, IL-35 has been suggested to enhance nT_{reg} proliferation^{58,59}. As IL-27 or IL-2 pretreatment upregulates IL12R β 2, this may also affect their sensitivity to IL-35²⁸. Although IL-23 is not known to affect nT_{regs}, it can limit TGF β -driven iT_{reg} development⁵². In contrast but IL-27 and IL-35 can mediate the development of distinct Foxp3⁻ iT_{reg} populations. While IL-27 can induce the development of an IL-10-producing Tr1-like regulatory population^{40–42,60}, IL-35 can induce the development of IL-35-producing iT_{reg}^{51,61}.

Taken together, these observations clearly show that the IL-12 family cytokines act as the immunological playmaker, shaping immune responses by directly inducing the development of T cell subpopulations and altering the function and fate of many cell populations that dictate disease outcome.

Appearances Can Be Deceiving: Similar Signals but Different Outcomes

These structural and functional observations present an important question; how do cells mediate divergent outcomes in response to seemingly similar signals generated by common signaling components? The importance of this question is emphasized by the fact that there are ~40 cytokines that signal through receptors that utilize a selection of only 4 JAKs and 7 STATs²⁷. There is considerable overlap in JAK/STAT usage within the IL-12 cytokine family with all the receptors signaling via JAK2 and three of the four receptors using STAT4 (Box 1; Fig. 1). These cytokines clearly mediate different downstream consequences and thus these signals must be interpreted differently.

Insight into one possible mechanism was recently provided by analysis of IL-35 receptor signaling. IL-35 signals via STAT1 and STAT4 to drive an inhibitory program, while interferon- γ (IFN- γ) and IL-12 in combination induce activation of the same STATs yet drive a prostimulatory program. The key distinguishing feature is the generation of STAT1:STAT4 heterodimers following IL-35 receptor ligation that does not occur

following combinatorial treatment with IFN- γ and IL-12²⁸. Furthermore, STAT1:STAT4 heterodimers, but not homodimers, were found to bind to STAT consensus sites within the *Ebi3* and *Ill2a* promoters, and mediate IL-35 production. Why STAT1:STAT4 heterodimers are only generated following IL-35 ligation remains to be determined, but could be due to the proximity of STAT1 and STAT4 phosphorylation favoring heterodimer formation. Indeed, the distribution of the IFNGR and the IL12R may not be uniform and is altered following T cell activation, suggesting that these receptors might even be actively segregated as a mechanism to actively prevent STAT1:STAT4 heterodimer formation⁶²⁻⁶⁴. Alternatively, IL-35 quantitatively promotes the generation of almost equal levels of pSTAT1 and pSTAT4 promoting heterodimerization, thereby leaving little free pSTATs for homodimerization. Given that the STAT DNA consensus binding motif (TTC-N₂₋₅-GAA) is not considered to vary considerably between the different STAT family members⁶⁵, it is also not clear why STAT1:STAT4 heterodimers uniquely bind to and transcribe *Ebi3* and *Ill2a* promoters while STAT1 and STAT4 homodimers do not. This infers that additional distinguishing differences must exist. This could include unique modifications and/or recruitment of co-activators via the distinctive STAT1:STAT4 carboxy-terminal transactivation domain combination that ultimately modifies binding and/or transcription^{66,67}.

Relatively few studies have suggested that STAT heterodimers can be generated following cytokine signaling. IFN γ can shift from a pro-inflammatory to an anti-inflammatory response by changing the relative expression and activation of STAT3. A dominant STAT3 response favors STAT1:STAT3 heterodimerization, thereby inhibiting homodimerization of STAT1 and the biological activities that are induced in response to STAT1 homodimers⁶⁸.

These observations raise the interesting hypothesis that STAT homodimers generate predominantly pro-inflammatory responses, while STAT heterodimers drive predominantly anti-inflammatory or inhibitory responses²⁷. Consistent with this hypothesis is the observation that IL-27 induces both pSTAT3 and pSTAT1 mediating T cell inhibition, and loss of STAT1 abrogates the suppressive effects of IL-27 by limiting the development of pSTAT-1:pSTAT-3 heterodimers (Fowler, Peters and Kuchroo, unpublished observations). Clearly, further analysis will be required to test this notion with signaling via the IL27R a particularly interesting candidate. Of course, the IL23R induces the activation of STAT3 and STAT4 so if heterodimers are generated this might undermine this hypothesis give the pro-inflammatory effects of IL-23, but availability of excess free pSTAT3 induced by IL-23 might be responsible for activating effects of IL-23. Alternatively, differential modifications and/or co-activator recruitment may be critical. Regardless, further examination of signaling via all the IL-12 cytokine receptors is likely to be extremely informative, not only for deciphering how these signals shape diverse functions but perhaps also established paradigms that might guide our understanding of cytokine signaling in general.

Future Questions and Challenges

Although substantial advances have been made in our understanding of this fascinating family of cytokines, much remains to be clarified and discovered. Its molecular complexities have also presented significant obstacles which will need to be overcome. For instance,

many of the knockout mice lack multiple cytokines greatly complicating data interpretation¹. The generation of mutant lines that lack a single, functional cytokine would be invaluable for detailed *in vivo* analysis with disease models. Likewise, the development of more specific neutralizing mAbs, more sensitive ELISA assay, and better reagents against receptor chains are sorely needed. Lastly, IL-35 has proven extremely difficult to produce limiting detailed functional analysis. In addition to these reagent issues, important questions remain.

First, are there any more members of this family? Given that IL-35 was only discovered five years ago it is possible that other combinations exist that either utilize known chains within this cytokine family or novel members.

Second, what is purpose and benefits (or limitations) of chain sharing? This could be a mechanism to create many cytokines with diverse functions from relatively few building blocks. Alternatively, by incorporating a protein into a positive and negative regulatory cytokine, genetic insults that alter the expression of these proteins may limit their physiological impact and disease consequences. Of course, the true importance for this unique feature may remain elusive.

Third, what is the extent and physiological impact of competition for cytokine or cytokine receptor chain pairing and binding? For instance, if p40 pairs with p35, does this limit IL-23 secretion? If IL-35 binds to IL12R β 2:gp130, does this limit the availability of the IL-12 and IL-27 receptors?

Fourth, how do seemingly similar signals generate diverse outcomes? The recent observation that part of the IL-35 inhibitory program is mediated by STAT1:STAT4 heterodimers in contrast to the STAT4 homodimers generated by IL-12 receptor signaling²⁸, presents one possible answer but also raises many questions. For instance, do other cytokines with inhibitory properties, such as IL-27, also generate heterodimers, while cytokines with pro-inflammatory properties, such as IL-23, do not? How do STAT heterodimers versus homodimers mediate such diverse functional programs?

Fifth, IL-27 has been shown to have both pro-inflammatory and anti-inflammatory effects. How the same cytokine induces pro-inflammatory and anti-inflammatory effects and under which context or combination needs to be resolved if IL-27 neutralization is going to be tested in a therapeutic setting.

In addition to these and other questions, there are considerable therapeutic implications and challenges. Cytokine neutralization or receptor blockade is inherently more challenging given the chain sharing propensity of this cytokine family. However, encouraging proof-of-principle does exist. For instance, mAbs specific for IL-12 have been generated (anti-p70), raising the possibility that mAbs could be raised to epitopes that are uniquely formed by a particular chain combination or neo epitopes induced allosteric changes induced upon pairing. Interestingly, recent insights into the dimer interface and mode of chain pairing have revealed some clear differences between the members of this cytokine family^{18,21}. This is most evident with IL-35, thereby validating the identification of mAbs that will only neutralize IL-35^{51,61}. Lastly, as discussed above, members of this cytokine family remain

very challenging to generate in high quantities limiting their therapeutic potential, inferring that some form of mutagenesis, without loss of biological activity, will probably be required. Despite the challenges that remain, it is likely that many surprising and exciting developments lie ahead.

Acknowledgments

Supported by the National Institutes of Health (AI091977 to D.A.A.V.; NS30843 to V.K.K.), an NCI Comprehensive Cancer Center Support CORE grant (CA21765; D.A.A.V.), and the American Lebanese Syrian Associated Charities (ALSAC; D.A.A.V.).

References

1. Collison LW, Vignali DA. Interleukin-35: odd one out or part of the family? *Immunol Rev.* 2008; 226:248–262. [PubMed: 19161429]
2. Jones LL, Vignali DA. Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily. *Immunol Res.* 2011
3. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. *Nat Rev Immunol.* 2005; 5:521–531. [PubMed: 15999093]
4. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. *Annu Rev Immunol.* 2007; 25:221–242. [PubMed: 17291186]
5. Langrish CL, et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. *Immunol Rev.* 2004; 202:96–105. [PubMed: 15546388]
6. Cox JH, et al. IL-27 promotes T cell-dependent colitis through multiple mechanisms. *J Exp Med.* 2011; 208:115–123. [PubMed: 21173106]
7. Wojno ED, Hunter CA. New directions in the basic and translational biology of interleukin-27. *Trends Immunol.* 2012; 33:91–97. [PubMed: 22177689]
8. Stumhofer JS, Hunter CA. Advances in understanding the anti-inflammatory properties of IL-27. *Immunol Lett.* 2008; 117:123–130. [PubMed: 18378322]
9. Pot C, Apetoh L, Awasthi A, Kuchroo VK. Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27. *Semin Immunol.* 2011; 23:438–445. [PubMed: 21893418]
10. Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. *Nat Rev Immunol.* 2008; 8:523–532. [PubMed: 18566595]
11. Wills-Karp M. IL-12/IL-13 axis in allergic asthma. *J Allergy Clin Immunol.* 2001; 107:9–18. [PubMed: 11149983]
12. Martin-Orozco N, Dong C. The IL-17/IL-23 axis of inflammation in cancer: friend or foe? *Curr Opin Investig Drugs.* 2009; 10:543–549.
13. Maloy KJ, Kullberg MC. IL-23 and Th17 cytokines in intestinal homeostasis. *Mucosal Immunol.* 2008; 1:339–349. [PubMed: 19079198]
14. Dong C. IL-23/IL-17 biology and therapeutic considerations. *J Immunotoxicol.* 2008; 5:43–46. [PubMed: 18382857]
15. McGeachy MJ, Cua DJ. The link between IL-23 and Th17 cell-mediated immune pathologies. *Semin Immunol.* 2007; 19:372–376. [PubMed: 18319054]
16. Kreymborg K, Bohlmann U, Becher B. IL-23: changing the verdict on IL-12 function in inflammation and autoimmunity. *Expert Opin Ther Targets.* 2005; 9:1123–1136. [PubMed: 16300465]
17. Crabe S, et al. The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling. *J Immunol.* 2009; 183:7692–7702. [PubMed: 19933857]
18. Lupardus PJ, Garcia KC. The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12. *J Mol Biol.* 2008; 382:931–941. [PubMed: 18680750]

19. Beyer BM, et al. Crystal structures of the pro-inflammatory cytokine interleukin-23 and its complex with a high-affinity neutralizing antibody. *J Mol Biol.* 2008; 382:942–955. [PubMed: 18708069]
20. Yoon C, et al. Charged residues dominate a unique interlocking topography in the heterodimeric cytokine interleukin-12. *EMBO J.* 2000; 19:3530–3541. [PubMed: 10899108]
21. Jones LL, Chaturvedi V, Uyttenhove C, Van SJ, Vignali DA. Distinct subunit pairing criteria within the heterodimeric IL-12 cytokine family. *Mol Immunol.* 2012.10.1016/j.molimm.2012.03.025
22. Stumhofer JS, et al. A role for IL-27p28 as an antagonist of gp130-mediated signaling. *Nat Immunol.* 2010; 11:1119–1126. This study provides one of the first clear indications that single chain components of the IL-12 cytokine family can act as competitive inhibitors. [PubMed: 21057510]
23. Cooper AM, Khader SA. IL-12p40: an inherently agonistic cytokine. *Trends Immunol.* 2007; 28:33–38. [PubMed: 17126601]
24. Khader SA, et al. Interleukin 12p40 is required for dendritic cell migration and T cell priming after *Mycobacterium tuberculosis* infection. *J Exp Med.* 2006; 203:1805–1815. [PubMed: 16818672]
25. Gately MK, et al. Interleukin-12 antagonist activity of mouse interleukin-12 p40 homodimer in vitro and in vivo. *Ann N Y Acad Sci.* 1996; 795:1–12. [PubMed: 8958912]
26. Gillessen S, et al. Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. *Eur J Immunol.* 1995; 25:200–206. [PubMed: 7843232]
27. Delgoffe GM, Murray PJ, Vignali DA. Interpreting mixed signals: the cell's cytokine conundrum. *Curr Opin Immunol.* 2011; 23:632–638. [PubMed: 21852079]
28. Collison LW, et al. The composition and signaling of the IL-35 receptor are unconventional. *Nat Immunol.* 2012; 13:290–299. In this study two unique and unusual aspects of IL-35 signaling are revealed. First, this study shows that IL-35 can signal via three receptors [IL12R β 2:gp130; IL12R β 2:IL12R β 2; gp130:gp130]. Second, IL-35 mediates part of its inhibitory program via STAT1:STAT4 heterodimers. [PubMed: 22306691]
29. Wang X, Lupardus P, Laporte SL, Garcia KC. Structural biology of shared cytokine receptors. *Annu Rev Immunol.* 2009; 27:29–60. [PubMed: 18817510]
30. Boulanger MJ, et al. Molecular mechanisms for viral mimicry of a human cytokine: activation of gp130 by HHV-8 interleukin-6. *J Mol Biol.* 2004; 335:641–654. [PubMed: 14672670]
31. Szabo SJ, Jacobson NG, Dighe AS, Gubler U, Murphy KM. Developmental commitment to the Th2 lineage by extinction of IL-12 signaling. *Immunity.* 1995; 2:665–675. [PubMed: 7796298]
32. Szabo SJ, Dighe AS, Gubler U, Murphy KM. Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. *J Exp Med.* 1997; 185:817–824. [PubMed: 9120387]
33. Rogge L, et al. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. *J Exp Med.* 1997; 185:825–831. [PubMed: 9120388]
34. Ma X, Trinchieri G. Regulation of interleukin-12 production in antigen-presenting cells. *Adv Immunol.* 2001; 79:55–92. [PubMed: 11680011]
35. Yamanouchi J, et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. *Nat Genet.* 2007; 39:329–337. [PubMed: 17277778]
36. Villarino AV, et al. Helper T cell IL-2 production is limited by negative feedback and STAT-dependent cytokine signals. *J Exp Med.* 2007; 204:65–71. [PubMed: 17227909]
37. Bancroft AJ, Humphreys NE, Worthington JJ, Yoshida H, Grencis RK. WSX-1: a key role in induction of chronic intestinal nematode infection. *J Immunol.* 2004; 172:7635–7641. [PubMed: 15187144]
38. Villarino AV, et al. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. *J Immunol.* 2005; 174:7684–7691. [PubMed: 15944269]
39. Pflanz S, et al. IL-27, a heterodimeric cytokine composed of EB13 and p28 protein, induces proliferation of naive CD4(+) T cells. *Immunity.* 2002; 16:779–790. [PubMed: 12121660]
40. Stumhofer JS, et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. *Nat Immunol.* 2007; 8:1363–1371. [PubMed: 17994025]

41. Fitzgerald DC, et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. *Nat Immunol.* 2007; 8:1372–1379. [PubMed: 17994023]
42. Awasthi A, et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. *Nat Immunol.* 2007; 8:1380–1389. References 40–42 show for the first time that IL-27 can induce IL-10 production and facilitate the development of Tr1 cells. [PubMed: 17994022]
43. Pot C, et al. Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. *J Immunol.* 2009; 183:797–801. [PubMed: 19570826]
44. Diveu C, et al. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. *J Immunol.* 2009; 182:5748–5756. [PubMed: 19380822]
45. Apetoh L, et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. *Nat Immunol.* 2010; 11:854–861. Reference 45, along with References 43 and 47, show that the IL-27 induced Tr1 program is driven by a c-Maf and AhR axis. [PubMed: 20676095]
46. Murugaiyan G, Mittal A, Weiner HL. Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-17-mediated autoimmune inflammation. *Proc Natl Acad Sci U S A.* 2010; 107:11495–11500. [PubMed: 20534530]
47. Gandhi R, et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. *Nat Immunol.* 2010; 11:846–853. [PubMed: 20676092]
48. Presky DH, et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. *Proc Natl Acad Sci U S A.* 1996; 93:14002–14007. [PubMed: 8943050]
49. Collison LW, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. *Nature.* 2007; 450:566–569. This study was the first to show that IL-35 is a novel inhibitory cytokine made by T_{regs}, which is required for their maximal inhibitory activity. [PubMed: 18033300]
50. Collison LW, Pillai MR, Chaturvedi V, Vignali DA. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. *J Immunol.* 2009; 182:6121–6128. [PubMed: 19414764]
51. Collison LW, et al. IL-35-mediated induction of a potent regulatory T cell population. *Nat Immunol.* 2010; 11:1093–1101. This study shows that that IL-35 can induce the development of an induced T_{reg} population, iT_{reg}35, which also suppress via IL-35. iT_{reg}35 can be induced by T_{regs} in inflammatory sites and contribute to infectious tolerance. [PubMed: 20953201]
52. Petermann F, et al. gammadelta T cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism. *Immunity.* 2010; 33:351–363. [PubMed: 20832339]
53. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. *Nat Immunol.* 2005; 6:1142–1151. [PubMed: 16227984]
54. D'Cruz LM, Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. *Nat Immunol.* 2005; 6:1152–1159. [PubMed: 16227983]
55. Villarino AV, et al. IL-27 limits IL-2 production during Th1 differentiation. *J Immunol.* 2006; 176:237–247. [PubMed: 16365415]
56. Dickensheets HL, Freeman SL, Donnelly RP. Interleukin-12 differentially regulates expression of IFN-gamma and interleukin-2 in human T lymphoblasts. *J Interferon Cytokine Res.* 2000; 20:897–905. [PubMed: 11054278]
57. Wojno ED, et al. A role for IL-27 in limiting T regulatory cell populations. *J Immunol.* 2011; 187:266–273. [PubMed: 21622862]
58. Niedbala W, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. *Eur J Immunol.* 2007; 37:3021–3029. [PubMed: 17874423]
59. Castellani ML, et al. IL-35, an anti-inflammatory cytokine which expands CD4+CD25+ Treg Cells. *J Biol Regul Homeost Agents.* 2010; 24:131–135. [PubMed: 20487626]

60. Batten M, et al. Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells. *J Immunol.* 2008; 180:2752–2756. [PubMed: 18292493]
61. Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA. Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. *J Immunol.* 2011; 186:6661–6666. [PubMed: 21576509]
62. Maldonado RA, et al. Control of T helper cell differentiation through cytokine receptor inclusion in the immunological synapse. *J Exp Med.* 2009; 206:877–892. [PubMed: 19349465]
63. Maldonado RA, Irvine DJ, Schreiber R, Glimcher LH. A role for the immunological synapse in lineage commitment of CD4 lymphocytes. *Nature.* 2004; 431:527–532. [PubMed: 15386021]
64. Canda-Sanchez A, et al. Differential distribution of both IL-12Rbeta chains in the plasma membrane of human T cells. *J Membr Biol.* 2009; 227:1–12. [PubMed: 19067026]
65. Ihle JN. STATs: signal transducers and activators of transcription. *Cell.* 1996; 84:331–334. [PubMed: 8608586]
66. Decker T, Kovarik P. Serine phosphorylation of STATs. *Oncogene.* 2000; 19:2628–2637. [PubMed: 10851062]
67. Decker T, Kovarik P. Transcription factor activity of STAT proteins: structural requirements and regulation by phosphorylation and interacting proteins. *Cell Mol Life Sci.* 1999; 55:1535–1546. [PubMed: 10526571]
68. Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses, Negative regulation of STAT1-dependent inflammatory gene activation. *J Biol Chem.* 2006; 281:14111–14118. [PubMed: 16571725]
69. Oppmann B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. *Immunity.* 2000; 13:715–725. [PubMed: 11114383]
70. Kobayashi M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. *J Exp Med.* 1989; 170:827–845. [PubMed: 2504877]
71. Chua AO, et al. Expression cloning of a human IL-12 receptor component. A new member of the cytokine receptor superfamily with strong homology to gp130. *J Immunol.* 1994; 153:128–136. [PubMed: 7911493]
72. Chua AO, Wilkinson VL, Presky DH, Gubler U. Cloning and characterization of a mouse IL-12 receptor-beta component. *J Immunol.* 1995; 155:4286–4294. [PubMed: 7594587]
73. Parham C, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. *J Immunol.* 2002; 168:5699–5708. [PubMed: 12023369]
74. Pflanz S, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. *J Immunol.* 2004; 172:2225–2231. [PubMed: 14764690]
75. Ihle JN. The Janus protein tyrosine kinase family and its role in cytokine signaling. *Adv Immunol.* 1995; 60:1–35. [PubMed: 8607368]
76. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. *Cell.* 2002; 109(Suppl):S121–S131. [PubMed: 11983158]
77. Thierfelder WE, et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. *Nature.* 1996; 382:171–174. [PubMed: 8700208]
78. Lucas S, Ghilardi N, Li J, de Sauvage FJ. IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms. *Proc Natl Acad Sci U S A.* 2003; 100:15047–15052. [PubMed: 14657353]
79. Hibbert L, Pflanz S, de Waal MR, Kastelein RA. IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. *J Interferon Cytokine Res.* 2003; 23:513–522. [PubMed: 14565860]
80. O'Shea JJ, Paul WE. Regulation of T(H)1 differentiation--controlling the controllers. *Nat Immunol.* 2002; 3:506–508. [PubMed: 12032561]
81. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. *Nat Rev Immunol.* 2005; 5:521–531. [PubMed: 15999093]

82. Bettelli E, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. *Nature*. 2006; 441:235–238. This study shows that IL-23 can facilitate the development of Th17 cells. [PubMed: 16648838]
83. Murphy CA, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. *J Exp Med*. 2003; 198:1951–1957. [PubMed: 14662908]
84. Batten M, et al. IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells. *J Exp Med*. 2010; 207:2895–2906. [PubMed: 21098093]
85. Molle C, Goldman M, Goriely S. Critical role of the IFN-stimulated gene factor 3 complex in TLR-mediated IL-27p28 gene expression revealing a two-step activation process. *J Immunol*. 2010; 184:1784–1792. [PubMed: 20083668]
86. Molle C, et al. IL-27 synthesis induced by TLR ligation critically depends on IFN regulatory factor 3. *J Immunol*. 2007; 178:7607–7615. [PubMed: 17548596]
87. Bauquet AT, et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. *Nat Immunol*. 2009; 10:167–175. [PubMed: 19098919]
88. Bettini M, Castellaw AH, Lennon GP, Burton AR, Vignali DA. Prevention of Autoimmune Diabetes by Ectopic Pancreatic beta-Cell Expression of Interleukin-35. *Diabetes*. 2012
89. Seyerl M, et al. Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC. *Eur J Immunol*. 2010; 40:321–329. [PubMed: 19950173]
90. Whitehead GS, et al. IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. *J Allergy Clin Immunol*. 2012; 129:207–215. [PubMed: 21906794]
91. Liu F, Tong F, He Y, Liu H. Detectable expression of IL-35 in CD4+ T cells from peripheral blood of chronic hepatitis B patients. *Clin Immunol*. 2011; 139:1–5. [PubMed: 21285006]
92. Wirtz S, Billmeier U, Mchedlidze T, Blumberg RS, Neurath MF. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. *Gastroenterology*. 2011; 141:1875–1886. [PubMed: 21820391]
93. Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. *J Immunol*. 2010; 184:7144–7153. [PubMed: 20483737]
94. Huang CH, et al. Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35. *J Immunol*. 2011; 187:462–471. [PubMed: 21613618]
95. Kuo J, Nardelli DT, Warner TF, Callister SM, Schell RF. Interleukin-35 enhances Lyme arthritis in *Borrelia*-vaccinated and -infected mice. *Clin Vaccine Immunol*. 2011; 18:1125–1132. [PubMed: 21613457]




Figure 1. Architecture of the IL-12 Cytokine Family

Diagram shows a schematic of the IL12 family cytokines, their receptors and JAK-STAT signaling partners. The Greed-Red bar along the bottom depicts their functional spectrum from most pro-inflammatory (IL-23) to most inhibitory (IL-35).




Figure 2. IL-12 Family Cytokines as an Immunological Nexus

Depicts the myriad of functional connections and effects mediated by members of the IL-12 cytokine family. Green arrows depict actions that result in pro-inflammatory/pro-stimulatory effects. Red arrows depict actions that result in inhibitory effects. Black arrows depict whether a particular event is up- (↓) or down- (↑) regulated.